# US 2013/0236929 A1 · Immortalized avian cell lines and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0236929 A1
- Document ID: US20130236929A1
- Status: Published application
- Kind: A1
- Application number: 13/775,314
- Filed: 2013-02-25
- Published: 2013-09-12
- Earliest claimed: 2009-05-12
- Assignees: Transgene S.A.
- Applicants: Transgene S.A.
- Inventors: Jean-Marc Balloul; Marina Kapfer; Thierry Menguy
- Web page: https://patentgrep.com/patent/US20130236929A1

## CPC

- C12N 7/025: {Packaging cell lines, e.g. transcomplementing cell lines, for production of virus}
- A61K 35/768: Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 7/02: Recovery or purification
- C12N 15/86: Viral vectors
- C12P 21/00: Preparation of peptides or proteins (single cell protein C12N1/00)
- C12N 2710/24152: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2710/24251: Methods of production or purification of viral material
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to specific immortalized avian cell lines expressing telomerase reverse transcriptase (TERT), and exhibiting distinct biologics production patterns. More particularly, the present invention relates to immortalized avian cell line capable of either amplifying Flaviviridae but not capable of amplifying Vaccinia virus strain Copenhagen (VV-COP) nor Modified Vaccinia virus Ankara (MVA), or capable of amplifying both Flaviviridae and Poxviridae. The invention further relates to the use of said immortalized avian cell lines and related methods for producing biologics, including viruses and proteins.

## Claims

### Claim at position 1

-24. (canceled)

### Claim 25

Use of the immortalized avian cell line deposited at the European Collection of Cell Cultures (ECACC) under accession number 08060502 and derivatives thereof, for the production of viruses and proteins.

### Claim 26

Use of the immortalized avian cell line deposited at the European Collection of Cell Cultures (ECACC) under accession number 08060501 and derivatives thereof, for the production of viruses and proteins.

### Claim 27 (depends on 25, 26)

Use according to claim 25 or claim 26, wherein the protein is selected in the group consisting of antibodies, receptor ligands, hormones, cytokines, growth factors, cell adhesion molecules, blood clotting factors, enzymes, fragments thereof, and combinations thereof.

### Claim 28 (depends on 25, 26)

Use according to claim 25 or claim 26, wherein the protein is selected in the group consisting of cytokines, antibodies, and hormones.

### Claim 29 (depends on 25, 26)

Use according to claim 25 or claim 26, wherein the protein is selected in the group consisting of IL-2, rituximab, and erythropoietin (EPO).

### Claim 30

A method for producing a protein comprising the steps of:
a) contacting an immortalized avian cell line deposited at the European Collection of Cell Cultures (ECACC) under accession number 08060502 with a recombinant vector comprising a nucleotide sequence coding the protein; and/or
b) cultivating the avian cell line under conditions which are enabling the protein to be produced.

### Claim 31

A method for producing a protein comprising the steps of:
a) contacting an immortalized avian cell line deposited at the European Collection of Cell Cultures (ECACC) under accession number 08060501, with a recombinant vector comprising a nucleotide sequence coding the protein; and/or
b) cultivating the avian cell line under conditions which are enabling the protein to be produced. Page 5

### Claim 32 (depends on 30, 31)

The method according to claim 30 or claim 31, wherein the protein is selected in the group consisting of antibodies, receptor ligands, hormones, cytokines, growth factors, cell adhesion molecules, blood clotting factors, enzymes, fragments thereof, and combinations thereof.

### Claim 33 (depends on 30, 31)

The method according to claim 30 or claim 31, wherein the protein is selected in the group consisting of cytokines, antibodies, and hormones.

### Claim 34 (depends on 30, 31)

The method according to claim 30 or claim 31, wherein the protein is selected in the group consisting of IL-2, rituximab, and erythropoietin (EPO).
